Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.
Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has added new features for user interaction, while several detailed data fields and options for downloading study information have been removed.SummaryDifference3%
- Check19 days agoChange DetectedThe website has been updated to version v2.12.2, introducing new features for downloading data in various formats and allowing users to select specific fields for export.SummaryDifference3%
- Check33 days agoChange DetectedThe website has been updated from version v2.12.0 to v2.12.1.SummaryDifference0.1%
- Check41 days agoChange DetectedThe website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential enhancements or features.SummaryDifference0.1%
- Check62 days agoChange DetectedThe website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.SummaryDifference0.1%
- Check70 days agoChange DetectedThe website has been updated to version v2.11.0, now displaying 'Results Submitted', while the previous version v2.10.5 has been removed along with the notice about delays in study record information.SummaryDifference0.8%
Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.